First M R
Division of Nephrology and Hypertension, University of Cincinnati Medical Center, Ohio 45267-0585, USA.
Pediatr Nephrol. 1995;9 Suppl:S40-2. doi: 10.1007/BF00867682.
The success rates of living-related donor (LRD) transplants are clearly superior to those obtained with cadaver donors. However, caution should be exercised when considering LRD transplantation for a condition which has an increased chance of recurring after transplantation and causing ultimate graft failure. The recurrence rate of focal segmental glomerulosclerosis (FSGS) in the allograft is 20%-40%, with graft failure resulting in 40%-50% of these cases. However, these figures may be an underestimation of the true rate of recurrence of FSGS. Once a first transplant fails due to recurrent disease, the risk of recurrence in the second transplant approaches 80%. Subgroups of patients at high risk for recurrence have been identified. In patients not at high risk for recurrent FSGS, the use of a LRD should be considered, provided that the donor and recipient and their families have been informed that the disease may recur and lead to graft failure. In patients at high risk for recurrence, a LRD transplant should be avoided. Hopefully, future development of a simple and reliable test to predict the likelihood of recurrence will enable us to counsel and advise our patients with FSGS about the wisdom or dangers of proceeding with a LRD transplant.
亲属活体供体(LRD)移植的成功率明显高于尸体供体移植。然而,对于移植后复发几率增加并最终导致移植失败的疾病,在考虑进行LRD移植时应谨慎。同种异体移植中局灶节段性肾小球硬化(FSGS)的复发率为20%-40%,其中40%-50%的病例会导致移植失败。然而,这些数字可能低估了FSGS的真实复发率。一旦首次移植因疾病复发而失败,第二次移植的复发风险接近80%。已确定了复发高危患者亚组。对于复发FSGS低风险的患者,如果已告知供体、受体及其家属该疾病可能复发并导致移植失败,则可考虑使用LRD。对于复发高危患者,应避免进行LRD移植。有望未来开发出一种简单可靠的检测方法来预测复发可能性,这将使我们能够就进行LRD移植的利弊向FSGS患者提供咨询和建议。